ArticlePharmaceuticals (Basel, Switzerland)2022

Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study.

Krisztina Bencsik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.